You have 9 free searches left this month | for more free features.

Intravenous human immunoglobulin

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Kawasaki Disease Trial in Shanghai (IVIG, Aspirin, Infliximab)

Withdrawn
  • Kawasaki Disease
  • Shanghai, China
  • +4 more
Mar 10, 2021

COVID, COVID-19, SARS-CoV-2 Trial in Worldwide (biological, other, drug)

Completed
  • COVID
  • +3 more
  • Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
  • +2 more
  • Colorado Springs, Colorado
  • +38 more
Mar 31, 2022

Primary Immune Thrombocytopenia Trial in Ukraine (Intravenous immunoglobulin (IVIG), 10% solution for infusion)

Recruiting
  • Primary Immune Thrombocytopenia
  • Intravenous immunoglobulin (IVIG), 10% solution for infusion
  • Kropyvnytskyi, Ukraine
  • +5 more
Aug 9, 2022

Aplastic Anemia Trial in Beijing (Ciclosporin, Avatrombopag, Anti-Human Thymocyte Immunoglobulin, Rabbit)

Not yet recruiting
  • Aplastic Anemia
  • Beijing, China
    Peking union medical college hospital
Aug 16, 2023

Obesity, Immune Deficiency Trial in Somerville (Institutional standard intravenous immune globulin treatment)

Recruiting
  • Obesity
  • Immune Deficiency
  • Institutional standard intravenous immune globulin treatment
  • Somerville, New Jersey
    Robert Wood Johnson University Hospital Somerset
Oct 10, 2022

HFRS (Hemorrhagic Fever With Renal Syndrome) Trial in China (IVIG 20g/d, IVIG 10g/d)

Recruiting
  • HFRS (Hemorrhagic Fever With Renal Syndrome)
  • IVIG 20g/d
  • IVIG 10g/d
  • Guangshui, Hu Bei Province, China
  • +8 more
Aug 22, 2023

Lymphoma Trial in Seattle (biological, other, procedure)

Not yet recruiting
  • Lymphoma
  • Immune Globulin Infusion (Human), 10% Solution
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 21, 2023

GVHD Trial in Ramat Gan (Cyclophosphamide, anti-human T-lymphocyte immunoglobulin (ATLG))

Recruiting
  • Graft Versus Host Disease
  • Ramat Gan, Israel
    Chaim Sheba Medical Center
May 4, 2022

Tetanus Trial in China (TNM002 (low dose), TNM002 (medium dose), TNM002 (high dose))

Completed
  • Tetanus
  • TNM002 (low dose)
  • +4 more
  • Shantou, Guangdong, China
  • +3 more
Nov 20, 2022

Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome Trial in Amsterdam (Immune Globulin Intravenous

Recruiting
  • Inflammatory Myopathy, Idiopathic
  • +5 more
  • Immune Globulin Intravenous (Human)
  • Placebo
  • Amsterdam, North- Holland, Netherlands
    Department of Neurology, Amsterdam UMC, location AMC
Apr 14, 2023

Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy Trial in Arlington Heights (Panzyga IVIG,

Not yet recruiting
  • Small Fiber Neuropathy
  • +3 more
  • Panzyga IVIG
  • Placebo
  • Arlington Heights, Illinois
    Northwest Community Healthcare
Aug 22, 2022

Primary Immunodeficiency Disease Trial (Boya IVIG)

Not yet recruiting
  • Primary Immunodeficiency Disease
  • Boya IVIG
  • (no location specified)
Nov 21, 2023

Primary Immunodeficiency Disease Trial in Hungary, Italy, Slovakia (Kedrion IVIG 10%)

Recruiting
  • Primary Immunodeficiency Disease
  • Kedrion IVIG 10%
  • Budapest, Hungary
  • +8 more
Jun 21, 2021

Intravenous Immunoglobulin Treatment in Chronic Inflammatory

Completed
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    • Paris, France
      Groupe Hospitalier Paris Saint-Joseph
    Mar 30, 2022

    Tetanus Trial in China (TNM002, Human tetanus immunoglobulin (HTIG))

    Recruiting
    • Tetanus
    • TNM002
    • Human tetanus immunoglobulin (HTIG)
    • Hefei, Anhui, China
    • +29 more
    Jan 19, 2023

    Guillain-Barré Syndrome Trial (Crovalimab, Placebo, Intravenous immunoglobulin therapy)

    Not yet recruiting
    • Guillain-Barré Syndrome
    • (no location specified)
    Aug 8, 2022

    Primary Immune Deficiency Disorder Trial (Immunoglobulin)

    Withdrawn
    • Primary Immune Deficiency Disorder
    • Immunoglobulin
    • (no location specified)
    Jul 1, 2020

    COPD Exacerbation Acute Trial in Rochester (CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy)

    Not yet recruiting
    • COPD Exacerbation Acute
    • CUVITRU - Ig subcutaneous human 20%
    • Standard Medical Therapy
    • Rochester, New York
    • +2 more
    Feb 28, 2023

    Total Knee Arthroplasty Trial in Chengdu (Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection

    Not yet recruiting
    • Total Knee Arthroplasty
    • Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)
    • Basic Treatment
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Jun 20, 2023

    Stroke Trial in Madrid (ApTOLL)

    Completed
    • Stroke
    • Madrid, Spain
      Clinical Pharmacology Department. Hospital Universitario de La P
    Oct 5, 2022

    Myasthenia Gravis Trial in Edmonton, Vancouver (Human normal immunoglobulin G (IgG))

    Recruiting
    • Myasthenia Gravis
    • Human normal immunoglobulin G (IgG)
    • Edmonton, Alberta, Canada
    • +1 more
    May 25, 2022

    Rabies Virus Infection Trial in Kunming (Natural full human mAb CBB 1 injection, Rabies Human Immunoglobulin (HRIG), Natural

    Not yet recruiting
    • Rabies Virus Infection
    • Natural full human monoclonal antibody CBB 1 injection
    • +3 more
    • Kunming, Yunnan, China
      The First Affiliated Hospital of Yunnan University of Traditiona
    Apr 14, 2023

    AL Amyloidosis Trial in Beijing

    Recruiting
    • AL Amyloidosis
      • Beijing, China
        Peking Union Medical College Hospital
      Apr 20, 2022

      Coronavirus Disease 2019 (COVID-19) Trial in Adelaide (CSL760)

      Terminated
      • Coronavirus Disease 2019 (COVID-19)
      • CSL760
      • Adelaide, Australia
        CMAX Clinical Research
      Dec 9, 2021

      Pregnancy Related Trial in Ukraine (Human Anti-D (rh) immunoglobulin)

      Recruiting
      • Pregnancy Related
      • Human Anti-D (rh) immunoglobulin
      • Cherkasy, Cherkasy Region, Ukraine
      • +15 more
      Jun 23, 2022